Aptimmune Biologics, an animal health company that specializes in creating swine vaccines, is relocating its headquarters and laboratory to the Bio-Research & Development Growth Park in St. Louis, Missouri’s 39 North innovation district. The company says the move was “due in large part to the exceptional financial and logistics support the company has received from investors and other businesses in the St. Louis area.”
“We had outgrown our original facilities, and after thorough evaluation of several sites nationwide, we made the decision to relocate our headquarters and laboratory to BRDG Park in St. Louis,” said Aptimmune CEO, Aaron Gilbertie.
39 North is Missouri’s new agtech innovation district, which covers nearly 600 acres in Missouri and includes many of the region’s top agtech companies including Monsanto, the Danforth Plant Science Center, Bio-Research & Development Growth (BRDG) Park and the Helix Center Biotech Incubator. 39 North is geared toward providing the lifestyle often sought by today’s highly skilled scientific workers, with a mix of retail, residential and office space connected by walking and biking trails.
“Aptimmune represents the type of fast growing, next generation animal health company that Missouri is excited to support,” said Bill Anderson, Executive Director of Missouri Technology Corp., which helped invest in Aptimmune. “Their decision to relocate to the 39 North innovation district is further proof of Missouri’s strength as a growing hub of ag tech innovation.”
For more information on why Missouri could be a prime location to launch or grow your business, contact Steve Johnson, CEO of Missouri Partnership, at 314.725.2688 or via our contact form, with any questions you might have, and learn how Missouri Partnership can help with your business expansion needs.